Dr. John David Stephens, MD

Dr. Stephens practices at Tyson Eye Care in Estero, Florida.

Dr. Stephens' NPI, 1134549967, was assigned on April 19, 2014. Dr. Stephens graduated from OU College of Medicine in 2014. Dr. Stephens holds Florida license ME139691.

Dr. Stephens' primary practice is Tyson Eye Care, at 8004 Vintage Pkwy, Estero, FL 33967 in Lee County. The practice phone is (239) 542-2020.

Dr. Stephens' primary practice is Tyson Eye Care in Estero, Florida. Dmand AI also links Dr. Stephens to 1 ambulatory surgery center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stephens practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Stephens' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Stephens is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Stephens' licenses on file in 3 states: Florida, South Dakota and Pennsylvania.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Stephens treats.

CMS data shows 4,412 Medicare services from Dr. Stephens across 20 procedure codes in 2024, for 776 Medicare patients. Medicare paid $537,863 for them.

CMS counts 776 Medicare patients who saw Dr. Stephens in 2024. The largest group is 65 to 74, with 344 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Stephens' median patient age at 74, with 54% women.

In 2024, Dr. Stephens wrote 2,627 Medicare Part D claims for 649 patients. 66% of them were for generic drugs. CMS names the drug for 2,491 of them, across 27 drugs with 11 or more claims each, at $597,324 in total drug cost. In 2023, CMS named 2,345 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Stephens for performance year 2024, reported individually. Dr. Stephens accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 506 procedures of cataract surgery by Dr. Stephens, more than 95% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Stephens, published from 2016 to 2024. 2019 was the busiest year, with 5. The most frequent topics are Antihypertensive Agents, Glaucoma Drainage Implants and Glaucoma, Open-Angle. Dr. Stephens has published most often in Clin Ophthalmol. Dr. Stephens' most frequent co-authors are John Palmer Berdahl, MD, Tanner J. Ferguson, MD and Michael Goldstein, MD.

Dmand AI links Dr. Stephens to 6 clinical trials, 2 of them phase 3 studies. Conditions studied include Refractive Errors, Presbyopia and Aphakia. Glaukos Corporation sponsors the most, 2.

CMS Open Payments shows 482 general payments to Dr. Stephens from 30 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Abbvie Inc. paid the most, $144,932. It also lists 1 research payment totaling $10,600 in 2025.

Dr. Stephens graduated from OU College of Medicine in 2014. Dr. Stephens is a member of AOA, AAO, AMA and ASCRS.

Dr. Stephens is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.